Chung et al. havedesigned a therapeutic nanocarrier for drug delivery using compounds derived from epigallocatechin gallate (EGCG), an antioxidant found in green tea. The sequential self-assembly of the EGCG derivative with trastuzumab led to the formation of stable micellar nanocomplexes. The authors then added a protective shell of polyethylene glycol and EGCG. When injected in breast cancer xenograft mouse models, these nanocomplexes had greater tumour selectivity and reduction — and longer blood half-life — than free trastuzumab.